A growing collection.
Always here to read.
Explore every article we have published, from the latest edition to earlier discoveries. Search a subject, choose a topic or revisit a particular month.
All articles
33 articles · Newest source date first
Oral TYK2–JAK1 inhibition produces broad improvement in dermatomyositis
The phase 3 VALOR trial found that brepocitinib improved muscle, skin and functional outcomes and allowed greater steroid reduction.
Read article →
FDA approvalOnce-weekly basal insulin Awiqli approved for adults with type 2 diabetes
Insulin icodec compresses basal insulin dosing from seven injections per week to one for eligible adults with type 2 diabetes.
Read article →
First approved therapy aimed at neurological manifestations of Hunter syndrome
Avlayah is designed to address a major limitation of conventional enzyme therapy: reaching the central nervous system.
Read article →
Obinutuzumab improves disease control in active systemic lupus erythematosus
The ALLEGORY trial provides phase 3 evidence that deeper B-cell depletion can improve global lupus disease activity when added to standard therapy.
Read article →
Large real-world study links GLP-1 use in type 1 diabetes with lower cardiovascular and kidney risk
A national electronic-health-record analysis found lower rates of major cardiovascular events and end-stage kidney disease among GLP-1RA initiators.
Read article →
Temporary mRNA CAR-T therapy points toward an outpatient 'immune reset' for myasthenia gravis
A BCMA-directed RNA CAR-T approach produced durable clinical effects without lymphodepletion in a small randomized study.
Read article →